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Background: Ustekinumab is a fully human monoclonal anti-
body approved for the treatment of chronic moderate-to-severe 
plaque psoriasis in adults. However, factors including effi-
cacy, tolerability, ease of use, and cost burden may affect us-
tekinumab utilization. Noncompliance may, in turn, affect 
treatment response. Objective: To evaluate ustekinumab uti-
lization in the real-world setting in Asia-Pacific countries. 
Methods: In this phase 4 observational study conducted in 
Indonesia, Malaysia, Singapore, Korea, and Taiwan, adults 
with plaque psoriasis receiving ustekinumab were followed 
for up to 52 weeks. Study endpoints were the proportion of 
all patients using ustekinumab according to label-recom-
mended intervals and the proportion of Korean patients who 
achieved a psoriasis area severity index 75 response at week 
16. Safety was assessed by monitoring adverse events. 
Results: Overall, 169 patients received ustekinumab (Korea, 
n=102; other countries, n=67). Just over half (56.2%) of pa-
tients used ustekinumab with the label-recommended inter-
val from baseline to week 40; the proportion was higher in 
Korea (73.5%) than in other countries (29.9%), probably be-
cause ustekinumab was provided without charge for Korean 
patients up to week 40. Noncompliance increased after 
week 40 in Korea and from week 28 in other Asia-Pacific 
countries, with cost cited as the most common reason. At 
week 16, 56.9% of Korean patients achieved a Psoriasis Area 
Severity Index 75 response. Safety results were in line with 
those seen in previous studies. Conclusion: More than half of 
all patients in Asia-Pacific countries used ustekinumab as per 
the label-recommended dose interval, but reimbursement 
variations between countries may have confounded overall 
results. (Ann Dermatol 28(2) 222∼231, 2016)
-Keywords-
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INTRODUCTION
Diseases of the skin cause a huge burden on global health, 
ranking as the 18th leading cause of disability-adjusted 
life-years worldwide1. Psoriasis, a chronic inflammatory 
skin disorder associated with several comorbidities, has 
been shown to negatively affect daily functioning and 
quality of life2-5. In Caucasian populations, psoriasis affects 
men and women equally, whereas in Mongoloid races, 
more men than women are affected5,6. Prevalence among 
Mongoloid races is somewhat lower than among Cauca-
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Fig. 1. Study design.
sians7, ranging from 0.2% in Taiwan5,7 and 0.3% in Korea8 
(population-based surveys) to 0.3% to 1.2% in Japan7,9 
and 1.1% to 5.5% in Malaysia7,9 (clinic-based studies).
Although the pathophysiology of psoriasis is not fully un-
derstood, cytokines such as interleukin (IL)-12, IL-23, and 
tumor necrosis factor-alpha (TNF-α) have been shown to 
play important roles in the development of lesions10. IL-12 
and IL-23 share a common subunit, p40, which has been 
shown to be overexpressed in psoriatic plaques11,12. 
Polymorphisms in the gene encoding p40 have also been 
linked to the pathophysiology of psoriasis13, making p40 a 
potential target for biologic therapies in psoriasis3. Usteki-
numab (StelaraⓇ; Janssen Biotech, Inc., Horsham, PA, 
USA) is a fully human monoclonal antibody with high 
specificity for the IL-12/23 p40 subunit, blocking bio-
logical activity and inhibiting signaling and subsequent 
downstream immune activation10. Ustekinumab is ap-
proved in multiple countries for the treatment of adults 
with chronic moderate-to-severe plaque psoriasis. In two 
phase 3, double-blind, placebo-controlled multicenter tri-
als (PHOENIX-1 and -2) involving 1,996 patients, sig-
nificantly more ustekinumab-treated patients achieved a 
psoriasis area severity index (PASI) 75 response at week 
12 compared with placebo (p＜0.0001)14,15. Ustekinumab 
has also been shown to be effective in Asian patients with 
moderate-to-severe psoriasis16-18. 
Long-term safety data indicate that up to 5 years of usteki-
numab treatment is generally well tolerated, with no evi-
dence of cumulative toxicity19,20, and ustekinumab-treated 
patients have expressed satisfaction with therapy21. However, 
for psoriasis treatment, many factors (e.g., perceived bene-
fit, tolerability, ease of use, and cost burden) are likely to 
determine adherence22, and poor adherence may in turn 
affect efficacy outcomes. Herein we describe the results of 
an observational study designed to evaluate how ustekinu-




This was a phase 4, multicenter, open-label, observational 
study (ClinicalTrials.gov identification number NCT0167-
7598) conducted from 29 November 2011 to 30 Novem-
ber 2013. Twelve study sites participated: one each in 
Indonesia, Singapore, and Taiwan; two in Malaysia; and 
seven in Korea. The study was performed in accordance 
with current guidelines on good clinical practice and appli-
cable regulatory- and country-specific requirements (Seoul 
National University, IRB No. B-1111-139-008; National 
Taiwan University Hospital, IRB No. 201202059RSA; 
Yonsei University, IRB No. 4-2011-0568; University of 
Indonesia, IRB No. 210/H2F1/ETIK/XII/2013; Malaysian 
Ministry of Health, IRB No. NMRR-11-633-9662; Singapore, 
IRB No. 2011/01877).
The study design is shown in Fig. 1. Patients were to be 
treated with ustekinumab for a duration of 52 weeks, with 
subcutaneous injections administered by the investigator 
or designee. Ustekinumab exposure was recorded during 
the initial study site visit (week 0) and at three subsequent 
visits (weeks 16, 28, and 52). In Korea, an additional two 
visits (weeks 4 and 40) were planned. 
The primary objectives of the study were twofold. The 
first was to determine how patients use ustekinumab 
(label-recommended or other/missed-dose interval) in 
Asia-Pacific countries. For the purposes of this analysis, 
label-recommended dosing was defined as week 0, week 
4, and every 12 weeks thereafter. Doses must have been 
taken within ±10 days of scheduled time. Once a patient 
received a dose outside the ±10-day interval, all sub-
sequent doses were considered noncompliant. The second 
objective was to evaluate efficacy in Korean patients by in-
vestigating the proportion of patients who achieved PASI 
75 responses at week 16.
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Patients
In all five Asia-Pacific countries, men and women aged 
≥18 years, with a diagnosis of plaque psoriasis according 
to the dermatologists’ clinical judgment, were eligible for 
inclusion in the study. Patients were required to agree to 
initiate treatment of ustekinumab on the same day as en-
rollment and were not permitted to have received any an-
ti-IL-12/23 therapy within six months prior to enrollment. 
All patients or their legal representatives signed informed 
consent forms prior to study initiation.
At the time of study initiation, ustekinumab was not being 
reimbursed in Korea. A local protocol amendment was is-
sued to apply the expected reimbursement guidelines for 
Korean patients. As a result, the Korean subset of patients 
were required to meet additional inclusion criteria, includ-
ing presence of plaque psoriasis for ≥6 months prior to 
the first administration of ustekinumab; PASI ≥10 at 
screening and at the time of the first administration of us-
tekinumab; plaque-type psoriasis covering at least 10% of 
total body surface area at screening and at the time of first 
administration of ustekinumab; and nonresponder to, in-
tolerant of, or with contraindications to systemic therapy 
(methotrexate or cyclosporine) or phototherapy for ≥12 
weeks prior to first administration of ustekinumab. 
Exclusion criteria included difficulty understanding ques-
tions posed by any of the questionnaires, current partic-
ipation in another clinical study, and active tuberculosis or 
other severe infections (e.g., sepsis, abscesses, or oppor-
tunistic infections).
Reimbursement and provision of study drug
Reimbursement varied significantly between participating 
countries when the study was conducted. Patients in 
Indonesia were required to self-pay (no reimbursement). 
Patients in Malaysia had to fail to respond to systemic 
therapy and had to still have severe disease (body surface 
area ≥30% or PASI ≥20) to qualify for government re-
imbursement; otherwise, they were required to self-pay. In 
Singapore, eligible patients had to have met means-tested 
criteria based on household income and had to have ex-
perienced failures of phototherapy and at least two oral 
systemic treatments. Reimbursement applications had to 
be renewed after 6 months; patients not eligible for re-
imbursement were required to self-pay. Patients in Taiwan 
were eligible for reimbursed treatment if they met mini-
mum baseline criteria of PASI ≥10, prior failure of 3 
months of phototherapy, and prior failure of at least two 
oral systemics—each of 3 months’ duration. The Taiwanese 
national health insurance system paid for the maintenance 
of biologic therapy only for patients in whom the initial re-
imbursement criteria were still met (PASI ≥10) and who 
had a PASI response ≥50% after three injections. In 
Korea, ustekinumab was provided free of charge through 
week 40 because of lack of reimbursement at the time of 
study initiation. Current reimbursement policy requires 
60% co-payment by the patient for biologics in dermato-
logic use. 
Because this was an observational study, patients received 
prescriptions from their physicians or health-care pro-
viders, and the medications were supplied by the phar-
macy or clinic. In Korea, commercial drug ustekinumab 
with additional protocol label was supplied to the inves-
tigational sites by the local sponsor, to be distributed to 
patients at each visit up to and including week 40. 
Patients received ustekinumab according to the recom-
mended dose instructions. For patients weighing ≤100 kg 
(220 lbs), each dose (week 0, week 4, and every 12 weeks 
thereafter) was 45 mg; for patients weighing >100 kg 
(220 lbs), each dose was 90 mg23,24. 
Endpoints and measurement tools
The primary endpoint of the study was ustekinumab 
usage. Frequency and percentage of patients in each cat-
egory (label-recommended or other/missed-dose intervals) 
and two-sided 95% confidence interval (CI) for percen-
tages were calculated. 
For the analysis of efficacy (prespecified endpoint for 
Korean patients), PASI score was determined. PASI is a 
physician-administered tool used for grading psoriatic le-
sion severity and therapeutic response, which produces a 
numeric score ranging from 0 (no disease) to 72 (maximal 
disease). The PASI assessment was performed by physi-
cians in all countries at screening/baseline and then at 
each clinic visit. Every effort was made to ensure con-
tinuity of the PASI administrator throughout the study to 
reduce interrater variability25. For Korean patients, counts 
and proportions of PASI 75 response over time were dis-
played with an estimated 95% CI. Comparison between 
observed and expected PASI 75 response rates was per-
formed using the normal approximation method.
The dermatology life quality index (DLQI) is a 10-item, pa-
tient-reported, quality-of-life questionnaire. It was com-
pleted by patients in all countries at screening/baseline 
and at each clinic visit. Change from baseline in DLQI 
was calculated for weeks 16, 28, 40 (Korea only), and 52.
A health economics/medical resource utilization ques-
tionnaire (HE/MRU) collected information on demography 
(patient living status), medical insurance, use of biologic 
agents, and use of phototherapy in all participating 
countries. Sections 1 and 2 of the questionnaire were 
completed by the patient; sections 3 and 4 were com-
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Table 1. Number of reimbursements of ustekinumab by country
Country Site
Payment method for ustekinumab 
(N=169)
Reimbursement Self-pay
Korea (n=102) 7 Free up to and including week 40
Indonesia (n=6) 1 0 6
Malaysia (n=11) 2 7 4
Singapore (n=15) 1 5 10
Taiwan (n=35) 1 16 19
pleted by the investigator. HE/MRU questionnaires were 
completed at screening/baseline and then at weeks 16, 
28, and 52.
Safety was assessed by monitoring adverse events (AEs) 
from the day of signing the informed consent form until 30 
days after the last study-related procedure. AEs were coded 
using the Medical Dictionary for Regulatory Activities 
(MedDRA Version 14.0; MedDRA MSSO, McLean, VA, 
USA). The incidence of treatment-emergent AEs (TEAEs) 
was summarized by severity and relationship to ustekinu-
mab by using the system organ class and preferred terms 
defined by MedDRA. Serious AEs and AEs of interest (e.g., 
infections, nonmelanoma skin cancer, other malignancies, 
major adverse cardiovascular events—including car-
diovascular death, myocardial infarction, and stroke—or 
any AE resulting in modification or discontinuation of us-
tekinumab) were also documented. Vital signs, physical 
examination results, weight, and waist circumference 
were also recorded.
Sample size and statistical analysis set
To determine the sample size for this study, it was as-
sumed that 50% of patients would use ustekinumab with 
label-recommended interval and 50% would not. With 
the planned number of 160 patients to be recruited and 
with an estimated dropout rate of 20%, it was determined 
that a precision of 17.9% width of the 95% CI could be 
obtained with approximately 128 patients who completed 
the study.
It was assumed that PASI response rates at week 16 would 
be lower than the rates observed in the PEARL study con-
ducted in Korea and Taiwan17, because eligible patients in 
the current study had more severe disease and were not 
required to undertake a washout period from prior thera-
pies, potentially resulting in first-visit PASI scores that 
were not reflections of true baseline disease. It was, there-
fore, determined that 84 Korean patients would be re-
quired for meaningful PASI results to be calculated; con-
sidering a 15% dropout rate, approximately 100 Korean 
patients should be recruited.
The full analysis set consisted of all patients who were en-
rolled and who received at least one dose of ustekinumab 
and completed postbaseline effectiveness measurements 
regardless of their compliance with the protocol. The safe-
ty analysis set consisted of all patients enrolled and who 
received at least one dose of ustekinumab. All analyses 
were descriptive in nature because there was no hypoth-
esis testing. PASI measurements were summarized by us-
ing mean, standard deviation (SD), median, minimum, 
and maximum values. 
RESULTS
Patients
Overall, 169 patients were enrolled into the study, of 
whom 102 were from Korea. Reimbursement details are 
shown in Table 1. Patient disposition is shown in Fig. 2. 
All 169 patients received ustekinumab and were included 
in the analyses. Both the full analysis set and the safety 
population therefore comprised 169 patients.
Baseline demographics are reported in Table 2. Overall, 
three-quarters of patients were male, with a median 
weight of 72 kg (159 lb); most patients (78%) used con-
comitant topical antipsoriatics during the study. Although 
baseline characteristics were broadly similar between pa-
tients from Korea and those from other Asia-Pacific coun-
tries, the PASI distribution varied. Owing to the additional 
inclusion criteria, no Korean patients had PASI ＜10, and 
more Korean patients had PASI scores ≥15. Furthermore, 
those from Korea were much less likely to have received 
prior biologic therapy (21.6%) compared with patients 
from the other four countries (50.7%). Results from the 
HE/MRU questionnaire indicated that 100% of patients in 
Korea had public health insurance, whereas in other 
Asia-Pacific countries, levels of public health insurance 
were lower (63%), and almost a quarter of patients (24%) 
had no health insurance coverage. Only one patient who 
paid for private insurance coverage was reimbursed a por-
tion of the psoriasis treatment costs, implying that the ma-
jority of patients either (1) had received prior treatments 
that were reimbursed by public health insurance or (2) 
were required to self-pay for nonreimbursed treatment.
Ustekinumab dosing schedule
The mean (SD) number of ustekinumab injections was 4.8 
(1.31) in Korean patients and 3.5 (1.44) in the remaining 
patients during the 52-week follow-up period. Primary 
analysis of the overall patient population showed that 
95/169 patients (56.2%; 95% CI, 48.7%∼63.7%) used us-
tekinumab at the label-recommended interval from base-
SW Youn, et al
226 Ann Dermatol
Table 2. Baseline demographics at study entry
Characteristic Korea (n=102) Other country (n=67) Overall (N=169)
Male gender, n (%) 76 (74.5) 52 (77.6) 128 (75.7)
Age at screening, yr
  Mean (SD) 44.5 (11.8) 46.1 (14.1) 45.1 (12.7)
  Median (range) 44.5 (18∼83) 45.0 (19∼86) 45.0 (18∼86)
Weight, kg
  Median (range) 72.0 (43.3∼107.0) 73.9 (42.1∼130.0) 72.0 (42.1∼130.0)
  ＜100, n (%) 99 (97.1) 59 (88.1) 158 (93.5)
PASI score
  Median (range) 16.7 (10∼72) 15.5 (2∼61) 16.4 (2∼72)
  ＜10, n (%) 0 (0) 20 (29.9) 20 (11.8)
  10∼14, n (%) 39 (38.2) 11 (16.4) 50 (29.6)
  ≥15, n (%) 63 (61.8) 36 (53.7) 99 (58.6)
Comorbidities, n (%)
  Any 39 (38.2) 36 (53.7) 75 (44.4)
  Obesity 1 (1.0) 2 (3.0) 3 (1.8)
  Diabetes 13 (12.7) 10 (14.9) 23 (13.6)
  Dyslipidemia 12 (11.8) 16 (23.9) 28 (16.6)
  Heart disease 31 (30.4) 27 (40.3) 58 (34.3)
Prior biologics, n (%)*,† 22 (21.6) 34 (50.7) 56 (33.1)
Prior systemic therapy, n (%)†,‡ 50 (49.0) 33 (49.3) 83 (49.1)
Prior phototherapy, n (%)†,§ 75 (73.5) 44 (65.7) 119 (70.4)
Disease duration, n (%)
  ＜10 yr 37 (36.3) 27 (40.3) 64 (37.9)
  ≥10 yr 65 (63.7) 40 (59.7) 105 (62.1)
Concomitant topical antipsoriatics, n (%)‖ 84 (82.4) 48 (71.6) 132 (78.1)
PASI: psoriasis area severity index, SD: standard deviation. *Includes adalimumab, alefacept, efalizumab, etanercept, infliximab, and
ustekinumab. †Data based on prior treatments up to 6 months before the first (baseline) visit. ‡Includes acitretin, cyclosporine, etretinate,
fumarates, methotrexate, and systemic corticosteroids. §Includes psoralen ultraviolet A and narrow-band ultraviolet B. ‖Includes daivobet,
calcipotriol, xamiol, coal tar, and coal tar solution.
Fig. 2. Patient disposition. Values are presented number (%).
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Table 4. Reasons for noncompliance (not receiving study drug as recommended)
Reason, n (%)
Korea (n=102) Other Asia-Pacific country (n=67)
Week 4 Week 16 Week 28 Week 40 Week 52 Week 4 Week 16 Week 28 Week 40 Week 52
Cost 0 0 0 0 34 (33.3) 0 5 (7.5) 10 (14.9) 4 (6.0) 14 (20.9)
Safety 0 0  1 (1.0) 0 1 (1.0) 1 (1.5) 2 (3.0) 1 (1.5) 1 (1.5) 1 (1.5)
Unable to attend 
  appointment
0 3 (2.9)  3 (2.9) 7 (6.9) 4 (3.9) 0 0 1 (1.5) 2 (3.0) 1 (1.5)
Patient choice 0 1 (1.0)  1 (1.0) 1 (1.0) 17 (16.7) 1 (1.5) 1 (1.5) 0 2 (3.0) 0
Physician judgment 0 0 0 0 9 (8.8) 0 1 (1.5) 3 (4.5) 0 2 (3.0)
Loss of efficacy 0 1 (1.0) 0 0 2 (2.0) 0 1 (1.5) 2 (3.0) 2 (3.0) 9 (13.4)
Other* 2 (2.0) 4 (3.9) 10 (9.8) 8 (7.8) 6 (5.9) 9 (13.4) 9 (13.4) 18 (26.9) 28 (41.8) 15 (22.4)
*Includes patients who attended the scheduled visit and were not dosed and for whom reasons for noncompliance were missing.
Table 3. Analysis of ustekinumab dosing schedule by study visit
Study visit
Patients receiving ustekinumab at the 
recommended interval, n (%)*
Korea (n=102) Other country (n=67)
Baseline 102 (100.0) 67 (100.0)
Week 4 100 (98.0) 56 (83.6)
Week 16 93 (91.2) 48 (71.6)
Week 28 85 (83.3) 30 (44.8)
Week 40 83 (81.4) 23 (34.3)
Week 52 25 (24.5) 13 (19.4)
*The recommended interval is week 0, week 4, and every 12
weeks thereafter. Dose must be taken within 10 days of 
recommended visit. Once a patient received a dose outside the
±10-day interval, all subsequent doses were considered 
noncompliant.
Fig. 3. Change in median PASI scores from baseline. (A) Korea. (B) Other Asia-Pacific countries. Compliant=taking ustekinumab in 
line with the recommended dosing (week 0, week 4, and every 12 weeks thereafter; dose to be taken within ±10 days). PASI: psoriasis 
area severity index.
line up to and including week 40. The proportion was 
much higher in Korean patients (75/102, 73.5%; 95% CI, 
65%∼82.1%) than in patients from the other Asia-Pacific 
countries (20/67, 29.9%; 95% CI, 18.9%∼40.8%) over 
40 weeks.
The numbers of patients receiving ustekinumab at the rec-
ommended dosing interval (week 0, week 4, and every 12 
weeks thereafter) are shown in Table 3. The compliance 
rate in Korean patients was higher than in other Asia-Pacific 
patients at all postbaseline visits; compliance appeared to 
decline from week 28 onward in non-Korean patients. 
There was a notable drop in compliance in Korean pa-
tients from weeks 40 to 52, which reflects the time point 
at which the drug was no longer provided for patients 
without charge. Noncompliant patients had less-frequent 
dosing than per label.
The reasons for not receiving the study drug as per the rec-
ommended dosing schedule (±10 days) are described in 
Table 4. In Korea, most of the noncompliance occurred at 
week 52, when the study drug was no longer provided for 
patients free of charge. As expected, the most common 
reason for noncompliance at that time point was cost 
(33.3%), followed by patient choice (16.7%). In the other 
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Table 5. Treatment-emergent adverse events (TEAEs)
TEAE
All ustekinumab-treated 
patients, n (%) (n=169)
Summary of TEAEs
  Any TEAE 110 (65.1)
  ≥1 TEAEs of interest*  55 (32.5)
  ≥1 serious TEAE 14 (8.3)
  TEAEs leading to dosage modification 
   or drug discontinuation
6 (3.6)
  Deaths  0 (0.0)
TEAEs in ≥2% of patients (system organ class, preferred term)
  Infections and infestations
    Nasopharyngitis  18 (10.7)
    Upper respiratory tract infection  17 (10.1)
    Tinea pedis  5 (3.0)
    Folliculitis  4 (2.4)
  Skin and subcutaneous tissue disorders
    Pruritus  17 (10.1)
    Urticaria  5 (3.0)
    Erythema  4 (2.4)
  Musculoskeletal and connective tissue disorders
    Arthralgia  5 (3.0)
    Back pain  4 (2.4)
    Psoriatic arthropathy  4 (2.4)
  Nervous system disorders
    Headache  5 (3.0)
  General disorders and administration site conditions
    Fatigue  4 (2.4)
  Injury, poisoning, and procedural complications
    Road traffic accident  4 (2.4)
  Vascular disorders
    Hypertension  4 (2.4)
*Includes infections, malignancies, and major cardiovascular 
events (e.g.,stroke, myocardial infarction, cardiovascular death).
Asia-Pacific countries, cost was a reason for noncom-
pliance from as early as week 16. More patients in those 
countries were also noncompliant at week 52 because of 
a loss of efficacy (20.9%), compared with patients in 
Korea (2.9%). 
Efficacy
The primary efficacy analysis for Korea showed that at 
week 16, 58/102 patients (56.9%; 95% CI, 47.3%∼
66.5%) achieved a PASI 75 response. At week 52, the 
PASI 75 rate in Korean patients was 70.6%. 
Changes in median PASI score from baseline are shown in 
Fig. 3. For the Korean population, the median PASI at 
baseline was 16.7 (range, 10∼72). The PASI score showed 
a consistent decline as early as week 4. For the four other 
Asia-Pacific countries, the median PASI score at baseline 
was 15.5 (range, 2∼61); these patients showed a similar 
decline in PASI score. In Korea, numerically larger mean 
changes from baseline in PASI were observed in the com-
pliant subgroup (−14.35 at week 16, −15.79 at week 28, 
and −16.36 at week 52) compared with the noncom-
pliant subgroup (−12.45, −13.26, and −11.61, respec-
tively). Similar changes were observed between compliant 
and noncompliant subgroups in the other Asia-Pacific 
countries. 
Mean changes from baseline in DLQI in the overall 
Asia-Pacific population at week 52 by PASI 50, 75, and 90 
responders were −7.5, −8.0, and −8.4 at week 16, and 
−8.1, −8.9, and −11.2, respectively, at week 52. Spear-
man’s correlation coefficients were 0.307 for week 16 and 
0.389 for week 52, indicating that the PASI response and 
the DLQI were positively correlated and maintained a pro-
portional relationship (i.e., patients showed linear im-
provement in both variables over the course of the study). 
That positive correlation was also demonstrated for the 
subgroup of Korean patients and for the subgroup of pa-
tients from the other Asia-Pacific countries.
Safety
TEAEs are shown in Table 5. Overall, 65.1% of patients 
reported at least one TEAE, although only 28.4% were as-
sessed by the investigator to be potentially drug related. 
The most commonly reported AEs were infections, of 
which the two most frequent were nasopharyngitis (10.7%) 
and upper respiratory tract infections (10.1%). The second 
most common class of TEAEs were skin disorders, of 
which the most frequently reported were pruritus (10.1%) 
and urticaria (3%). Four patients (2.4%) had a TEAE that 
led to discontinuation of treatment.
During the study period, 14 patients (8.3%) had serious 
AE. These were bone fracture (n=3), malignancy (n=2), 
and one case each of myocardial infarction, pustular psor-
iasis, psoriatic arthropathy, hypertension, pyrexia, pneu-
monia, limb injury, epistaxis, and vocal cord polyp. TEAEs 
of interest based on theoretical risks associated with 
IL-12/23 inhibition (infection, malignancy) and/or pop-
ulation risks in patients with psoriasis (major adverse car-
diovascular events) were also evaluated. Overall, 32% of 
patients reported infections—including one case of pneu-
monia—but no cases of tuberculosis or opportunistic 
infections. There were two malignancies: one case of co-
lon cancer and one of recurrent hepatocellular carcinoma 
(HCC). One myocardial infarction was reported, in a pa-
tient with a preexisting history of cardiovascular disease.
No clinically significant changes in vital signs and phys-
ical findings were observed during the study. No deaths 
occurred during the study period, although the patient 
with recurrent HCC died after completion of the study.
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DISCUSSION
This was a phase 4, multicenter, open-label observational 
study designed to determine how patients use ustekinu-
mab in a naturalistic setting in the Asia-Pacific region and 
to examine efficacy outcomes in Korean patients. 
More than half of Asia-Pacific patients used ustekinumab 
according to the label-recommended schedule; however, 
higher compliance rates were observed up to week 40 in 
the Korean population when ustekinumab was provided 
free of cost; after week 40, compliance declined noticeably. 
Compliance also declined from week 28 onward in pa-
tients from the other Asia-Pacific countries, with cost and 
efficacy cited as major reasons for discontinuing or delay-
ing treatment. Cost therefore appears to be an important 
driver for not receiving the drug at the recommended 
schedule. As such, the results of clinical trials using bio-
logic therapies may differ from real-life clinical situations 
in which patients are required to self-pay or co-pay for 
treatment. Patients may be less likely to use non-
reimbursed medication regardless of efficacy, or they may 
delay treatments beyond the recommended intervals in an 
attempt to reduce costs. Of note, fewer Korean patients in 
this study had received prior biologic therapy compared 
with patients in other Asia-Pacific countries—possibly be-
cause of lack of reimbursement for these therapies in 
Korea as a result of health insurance guidelines26, and be-
cause of patients’ unwillingness or inability to self-pay.
Our study has several important limitations, including 
small numbers of patients, different entry criteria between 
patients from Korea and other Asia-Pacific countries, and 
the provision of the drug for free in Korea up to only 
week 40 because of lack of reimbursement in Korea at the 
time of study initiation. The countries involved in the 
study had different reimbursement criteria from one anoth-
er, and those criteria are likely to have affected treatment 
compliance in different ways. As such, only generalized 
conclusions can be drawn related to how treatment cost 
may affect whether patients elect to receive treatment at 
the recommended dosing intervals or instead become 
noncompliant. 
Efficacy evaluations constituted a prespecified endpoint 
for the Korean population. Although efficacy data were 
subject to the same limitations described earlier, never-
theless there appears to be a consistent decline in disease 
severity from as early as week 4. Exploratory analysis also 
indicated a consistent decline in median PASI scores in 
patients from other Asia-Pacific countries. However, be-
cause of the uncontrolled and open-label nature of the 
study, analyses of PASI 75 responses are difficult to con-
textualize accurately. Lack of inclusion criteria that specify 
prior drug washout periods may suggest that the ob-
servations seen at baseline are not true representations of 
treatment-naive baseline values. Thus, for this study de-
sign, the results showing absolute PASI values over time 
may be more meaningful measures of efficacy.
Safety evaluations were in line with previous reports about 
ustekinumab. A previous study with ustekinumab in-
dicated that the risk/benefit of ustekinumab treatment 
should be carefully assessed in patients with hepatitis C vi-
rus (HCV) and/or HCC because there is a theoretical risk 
of virus reactivation during treatment with ustekinumab27. 
In the present study, one patient with HCV and a history 
of HCC suffered a relapse of the HCC during the treatment 
period. However, the patient had an incomplete resection 
of the prior HCC and was treated with an anti-TNF agent 
subsequent to the resection and prior to ustekinumab 
treatment. 
In conclusion, more than half of all Asia-Pacific patients 
used ustekinumab as per label-recommended dose inter-
val, but reimbursement variations between countries may 
have confounded the overall results. Ustekinumab was 
efficient in treating patients with plaque psoriasis in the 
real-world setting in Asia Pacific countries, and compliant 
patients received slightly greater efficacy benefits. Usteki-
numab was generally well tolerated in this population, 
with a safety profile consistent with that reported in the 
prescribing information.
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